- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| 12.02. | ADS-TEC Energy - Positive progress in 2024 | 343 | ADS-TEC reported record revenue, albeit below previous guidance, despite 2024 being a more challenging period for EVs and associated infrastructure-related companies and some revenue deferrals into... ► Artikel lesen | ||
| 12.02. | Lime Technologies (STO: LIME) hits FY24 targets | 220 | Lime Technologies reported Q424 revenue growth of 18.9% y-o-y, with an EBITA margin of 25.6% and growth in annual recurring revenue of 30% y-o-y. For FY24, revenue was 18.8% higher (beating the 18%... ► Artikel lesen | ||
| 11.02. | MJ Gleeson (LON: GLEE) - Interims point to improving H2 | 179 | MJ Gleeson has delivered a resilient first-half performance despite a subdued market, with Gleeson Homes growing sales volumes and increasing its forward order book. The 10% rise in Gleeson Homes' revenue... ► Artikel lesen | ||
| 11.02. | Dunelm Group (LSE: DNLM) - H125 results resilient and CEO to retire | 293 | Dunelm Group's H125 results reflect a resilient performance despite macroeconomic pressures, with low-single-digit sales growth and limited profit growth. The 2.4% revenue growth to £894m underscores... ► Artikel lesen | ||
| 10.02. | VEON - An innovative approach to frontier telecoms | 3.821 | VEON is a frontier market telecommunications operator offering traditional mobile and internet, and innovative digital services such as online payments, music and TV streaming, and IT services. It has... ► Artikel lesen | ||
| 10.02. | Safari Investments - Portfolio optimisation to enhance value | 169 | Safari Investments (SAR) is a retail property specialist that owns and operates suburban shopping centres in South Africa and Namibia: four small regional shopping centres and four community centres.... ► Artikel lesen | ||
| 10.02. | Zinc (LSE: ZIN) starts new year with strong momentum | 348 | Zinc's full-year trading update indicates adjusted EBITDA up 50% at £1.5m, on revenues down from £40m to £32m as the business changes shape, with non-core elements exited. The group has had a series... ► Artikel lesen | ||
| 10.02. | EnSilica (LSE:ENSI) - commercial momentum should support rapid scaling in revenues. | 194 | EnSilica's H1 FY25 results demonstrate robust commercial and operational progress, masked by a 3% revenue dip to £9.3 million. However, mix improved substantially, with chip supply revenue grew 164%... ► Artikel lesen | ||
| 06.02. | Basilea Pharmaceutica - Encouraging start to the year for Cresemba | 331 | Basilea Pharmaceutica has continued its strong momentum into 2025, announcing the receipt of a CHF1.2m milestone payment for Cresemba for the strategically important Japanese market. This marks the... ► Artikel lesen | ||
| 06.02. | Target Healthcare REIT - Income and capital growth continuing | 225 | Indexed rent reviews continue to drive earnings growth and property valuation uplifts at Target Healthcare REIT. Meanwhile, tenant profitability remains strong, reflected in a continuing high level... ► Artikel lesen | ||
| 05.02. | Metals One - Black Schist moves to the next stage | 333 | Metals One announced on 31 January the results of the preliminary economic assessment (PEA) into its Black Schist project, compiled by Wardell Armstrong. Of its two deposits, the key economic driver... ► Artikel lesen | ||
| 05.02. | James Fisher (LSE: FSJ) - FY24 trading update implies progress towards targets in FY25 | 320 | James Fisher is starting to see the benefits of its transformation programme coming through. In H224, trading across the business was solid, supported by structural growth in end markets. FY24 underlying... ► Artikel lesen | ||
| 05.02. | Basilea Pharmaceutica (SIX: BSLN) records first commercial milestone payment from Japan | 318 | Basilea Pharmaceutica has announced the receipt of its first commercial milestone payment of CHF1.2m from partner Asahi Kasei Pharma (AKP) for reaching an undisclosed sales threshold in Japan for its... ► Artikel lesen | ||
| 04.02. | Finsbury Growth & Income Trust - Exciting times - more UK and zero overseas | 229 | Finsbury Growth & Income Trust's (FGT's) portfolio has changed considerably since 2019. There is a greater exposure to digital winners, which now make up close to two-thirds of the fund, a lower weighting... ► Artikel lesen | ||
| 04.02. | NWF Group (LON: NWF) - H1 profits up 25%, outlook encouraging | 285 | NWF Group increased H1 operating profit by 21% to £5.0m and retained a strong balance sheet with net cash of £11.4m (H123: £13.3m), driven by robust trading. The key drivers of growth were the Fuels... ► Artikel lesen | ||
| 03.02. | HgT - Transaction activity picked up in 2024 | 200 | HgT reported a robust 10.1% preliminary NAV total return (TR) in FY24 (of which 4.4% in Q424), which the company highlighted was primarily driven by the strong trading performance of the underlying... ► Artikel lesen | ||
| 03.02. | IRLAB Therapeutics - Phase I data supports IRL757's development | 219 | IRLAB Therapeutics has reported positive top-line data from one of the two ongoing Phase I clinical trials evaluating its third clinical-stage asset, IRL757, as a potential treatment for apathy. This... ► Artikel lesen | ||
| 03.02. | Sylvania Platinum - Cost control and production improvements | 1.442 | Sylvania Platinum's Q225 production increased by 7.4% on Q125, driving a 104% increase in EBITDA to US$6.7m, supported by cost control and a small increase in the average platinum group metals (PGM)... ► Artikel lesen | ||
| 03.02. | The Platform Group - Feedback from January 2025 CMD | 336 | At The Platform Group's (TPG's) January 2025 capital markets day (CMD), management provided an overview of the headline FY24 results (above guidance) and updated future guidance released that day. TPG... ► Artikel lesen | ||
| 31.01. | Herantis (HEL: HRTIS) presents positive Phase Ib update | 219 | Herantis Pharma has announced an encouraging update from its ongoing Phase Ib trial for lead asset HER-096, which is being developed as a potential disease-modifying treatment for Parkinson's disease... ► Artikel lesen | ||
| 31.01. | IRLAB Therapeutics (STO: IRLAB-A) reports positive Phase I data for IRL757 in elderly cohort | 253 | IRLAB Therapeutics has reported positive top-line data from one of two ongoing Phase I studies evaluating the drug candidate IRL757 as a treatment for apathy. This study, financed by the McQuade Center... ► Artikel lesen | ||
| 31.01. | IRLAB (STO: IRLAB-A) reports positive Phase I data for IRL757 in elderly cohort | 267 | IRLAB Therapeutics has reported positive topline data from one of two ongoing Phase I studies, evaluating the drug candidate IRL757 as a treatment for apathy. This study, financed by the McQuade Center... ► Artikel lesen | ||
| 30.01. | OSE (PAR: OSE) launches AI immunotherapy partnership | 198 | OSE has signed a strategic partnership with Scienta Lab, aiming to model inflammatory diseases and identify predictive biomarkers of efficacy for immunotherapies. Scienta Lab is a France-based leader... ► Artikel lesen | ||
| 29.01. | Dowlais Group - American Axle & Manufacturing agreed offer | 1.491 | In 2024, Dowlais Group exited its loss-making Hydrogen business and announced a strategic review of Powder Metallurgy. The group has now announced an agreed offer from American Axle & Manufacturing... ► Artikel lesen | ||
| 29.01. | Biomea Fusion - An innovative approach to diabetes and obesity | 374 | Biomea Fusion is a clinical-stage biopharmaceutical company developing novel small molecules to cure metabolic diseases. Its proprietary FUSION System platform has created a pipeline of covalent candidates... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
